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ABSTRACT:  After consumption of plant-derived foods or beverages, dietary polyphenols 28 
such as quercetin are absorbed in the small intestine and metabolized by the body, or are 29 
subject to catabolism by the microbiota followed by absorption of the products by the colon. 30 
The resulting compounds are bioavailable, circulate in the blood as conjugates with 31 
glucuronide, methyl or sulfate groups attached, and are eventually excreted in the urine. In 32 
this review, the various conjugates from different intervention studies are summarized and 33 
discussed. In addition, the substantial variation between different individuals in the measured 34 
quercetin bioavailability parameters is assessed in detail by examining published human 35 
intervention studies where sources of quercetin have been consumed in the form of food, 36 
beverages or supplements. It is apparent that most reported studies have examined quercetin 37 
and/or metabolites in urine and plasma from a relatively small number of volunteers. Despite 38 
this limitation, it is evident that there is less inter-individual variation in metabolites which 39 
are derived from absorption in the small intestine compared to catabolites derived from the 40 
action of microbiota in the colon. There is also some evidence that a high absorber of intact 41 
quercetin conjugates could be a low absorber of microbiota-catalyzed phenolics, and vice 42 
versa. From the studies reported so far, the reasons or causes of the inter-individual 43 
differences are not clear, but, based on the known metabolic pathways, it is predicted that 44 
dietary history, genetic polymorphisms, and variations in gut microbiota metabolism would 45 
play significant roles. In conclusion, quercetin bioavailability is subject to substantial 46 
variation between individuals, and further work is required to establish if this contributes to 47 
inter-individual differences in biological responses. 48 
 49 
  50 





Introduction  51 
 52 
Quercetin is a polyphenolic compound of the flavonoid class (sub-class flavonol) and 53 
is regularly consumed in the diet. Rich sources are kale, onion, various berries, apples, 54 
black tea and red grapes (Perez-Jimenez and others 2010, Perez-Jimenez and others 55 
2011), and certain commercially available food supplements (Serra and others 2012). 56 
Quercetin safety has been critically reviewed (Okamoto 2005, Harwood and others 57 
2007) and high-purity quercetin was given Generally Recognized As Safe (GRAS) 58 
status in 2010 (FDA 2010). Over the last few decades, a large number of biological 59 
studies on quercetin have been published, reporting a wide range of biological effects 60 
in vitro and in vivo including anti-inflammatory and neuroprotective activities 61 
(Okamoto 2005, Harwood and others 2007, Boots and others 2008, Gibellini and 62 
others 2011, Dajas 2012, Russo and others 2012, Kawabata and others 2015, Kerimi 63 
and Williamson 2017).  64 
 65 
Quercetin Metabolism after Consumption in Humans 66 
The pathways of quercetin absorption in the gastrointestinal tract of humans and other 67 
mammals are quite well understood (Crozier and others 2010, Del Rio and others 68 
2013). Only a minor proportion of quercetin is absorbed in the stomach (Crespy and 69 
others 2002), and the primary site of absorption is the small intestine (Graefe and 70 
others 1999, Ader and others 2000, Erlund and others 2000). In planta, quercetin is 71 
found attached to sugars, since the aglycone is highly reactive and relatively insoluble 72 
in aqueous media (Azuma and others 2002, Smith and others 2011). The absorbed 73 
“unit” of quercetin is the aglycone itself, and before absorption into the enterocyte, any 74 
attached chemical groups such as sugars must be removed. This is achieved by brush 75 





border enzymes such as lactase phloridzin hydrolase, which remove glucose groups 76 
from flavonols (Day and others 2000). Paradoxically, quercetin glycosides are 77 
generally more bioavailable than the aglycone since the latter is more insoluble in the 78 
lumen of the gut (Hollman and others 1995, Hollman and others 1996, Hollman and 79 
others 1997a). Since the brush border enzymes are specific for glucose, quercetin 80 
glucosides are absorbed more quickly than other types of glycosides, for example rutin 81 
(quercetin-3-O-rutinoside), which can only be deglycosylated to quercetin aglycone by 82 
enzymes from the gut microbiota (Cermak and others 2003, Arts and others 2004, 83 
Reinboth and others 2010, Russo and others 2012). The importance of solubility is 84 
apparent from studies on the bioavailability of quercetin in pigs, rats and humans, 85 
which can be enhanced when administered in combination with a high fat (17%) diet 86 
(Lesser and others 2004, Guo and others 2013), alcohol (Dragoni and others 2006) or 87 
with non-digestible oligosaccharides (Matsukawa and others 2009). After absorption 88 
by enterocytes, quercetin is glucuronidated by UDP-glucuronosyl transferases (UGTs), 89 
sulfated by sulfotransferases (SULTs) and/or methylated by catechol-O-methyl 90 
transferase (COMT) present in intestinal and hepatic cells (Fig. 1). These 91 
biotransformation reactions are also observed in rat or human hepatocytes in vitro 92 
(Vacek and others 2012). Once absorbed, quercetin enters the bloodstream and appears 93 
as various different chemical species, including methylated forms. In plasma, 78-79% 94 
was estimated as conjugates of quercetin, 10-13% as tamarixetin (4′-O-methyl-95 
quercetin) and 8.5-11% as isorhamnetin (3′-O-methyl-quercetin) conjugates (Cermak 96 
and others 2003, Lesser and others 2004, Reinboth and others 2010). A significant 97 
proportion of conjugated flavonoids are excreted back into the intestinal lumen by 98 
enterocytes via multidrug resistance-associated protein 2 (MRP2 (ABCC2)) or breast 99 
cancer resistance protein (BCRP (ABCG2)) (Cermak and Wolffram 2006). Quercetin 100 





glucuronides serve as a more stable form of quercetin for transport in the bloodstream, 101 
but may be deconjugated for example in vascular smooth muscle cells (Menendez and 102 
others 2011, Galindo and others 2012) and at sites of inflammation (Shimoi and others 103 
2001, Menendez and others 2011, Kawai 2014, Perez and others 2014). The 104 
conjugates themselves generally have diminished biological activity compared to the 105 
aglycone, but there are exceptions to this, and sometimes, conjugated and/or 106 
methylated metabolites display biological activity distinct from that of the parent 107 
compound (Williamson and others 2005, Tribolo and others 2008, Lodi and others 108 
2009, Beekmann and others 2012, Araujo and others 2013). Quercetin derivatives, 109 
such as rutin, which are not absorbed in the small intestine, pass to the colon, where 110 
they undergo deglycosylation by α-rhamnosidases and β-glucosidases produced by the 111 
gut microbiota. The resulting aglycone is then absorbed by the colonocytes and passes 112 
into the circulation, or is subject to catabolic reactions to form lower molecular weight 113 
phenolic species, as outlined in Fig. 2. Quercetin was transformed by certain strains of 114 
Pediococcus spp., Streptococcus spp., Lactobacillus spp., Bifidobacterium spp. and 115 
Bacteroides spp. to various phenolic (3-hydroxybenzoic, 3,4-dihydroxybenzoic and 116 
3,4-dihydroxyphenylacetic) acids (Cermak and others 2006). Quercetin was also 117 
metabolized by porcine hindgut contents in vitro (Cermak and others 2006). After 118 
quercetin in vitro colonic fermentation with rat feces for 48 h, the main product was 119 
protocatechuic acid with lower amounts of homovanilic, phenylacetic, and p-120 
hydroxybenzoic acids (Serra and others 2012). Similar degradation products were 121 
observed when quercetin was exposed to exhaustive electrochemical hydrolysis 122 
(Sokolova and others 2011, Ramesova and others 2012, Sokolova and others 2012). 123 
Degradation of quercetin by rat gut microbiota therefore involves C-ring fission, 124 
formation of 3-(3,4-dihydroxyphenyl)propionic acid, and subsequent transformation to 125 





3,4-dihydroxyphenylacetic acid. Further transformation leads to protocatechuic acid 126 
and then to 4-hydroxybenzoic acid. 3,4-Dihydroxyphenylacetic acid can also be 127 
dehydroxylated to m- or p-hydroxyphenylacetic and phenylacetic acids (Fig. 2) (Serra 128 
and others 2012). These compounds are further degraded into various simpler products 129 
and finally to carbon dioxide (Walle and others 2001, Walle 2004).  130 
 131 
The main pathways of metabolism of quercetin depend on conjugating enzymes, most 132 
of which have known genetic polymorphisms, but are also inducible by drugs, food, 133 
environment. Quercetin catabolism is also affected by microbiota composition, which 134 
is influenced by multiple factors. It is not surprising, therefore, that there is substantial 135 
inter-individual variation in absorption and metabolism of quercetin between 136 
individuals. This has been observed for other groups of polyphenols. For example, the 137 
metabolism of ellagitannins in humans shows several metabolizing phenotypes, or 138 
“metabotypes” (Gonzalez-Sarrias and others 2017). These phenotypes are determined 139 
by the concentration and activity of intestinal carriers and post-absorptive phase I and 140 
phase II metabolizing enzymes, and by the composition and activities of the gut 141 
microbiota, many of which will be influenced by the genotype of the subject (Yousri 142 
and others 2014). Pharmacogenomic studies have demonstrated that for some drugs, 143 
individuals can be categorized into poor, intermediate or extensive absorbers or 144 
metabolizers, and dosing has to be adapted clinically (Kaddurah-Daouk and others 145 
2014). Plant food phytochemicals are absorbed and metabolized through the same 146 
polymorphic carriers and enzymatic systems as drugs, and so their pharmacokinetics 147 
are also likely to depend on the same determinants.  148 
 149 





In this review, we have examined inter-individual variation in quercetin bioavailability 150 
by systematically assessing published human studies dealing directly or indirectly with 151 
this subject. Bioavailability has several definitions, but it is generally regarded as 152 
representing the amount of a substance that reaches a given site of action. For 153 
polyphenols, this is usually considered as the amount which appears in plasma. The 154 
minimum bioavailability can also be estimated as a percentage of dose based on 155 
urinary measurement of the compound and its metabolites (Hollman and Katan 1999, 156 
Pérez-Jiménez and others 2010). A comparable term is ADME (absorption, 157 
metabolism, disposition and excretion) which can be applied to polyphenols but is 158 
more often used in the pharmaceutical area (Prot and others 2014). Here, the term 159 
bioavailability is used for convenience but is used in a relative sense so that different 160 
sources and different derivatives can be compared (Rescigno and others 1994, 161 
Schlemmer 1995).  162 
 163 
Assessment of the Literature for Studies on Quercetin Bioavailability  164 
In order to find as many papers as possible and remove any bias, we performed a 165 
systematic search for papers on flavonol bioavailability in humans, and then further 166 
refined it by examining each paper for data on inter-individual variation. The search 167 
was conducted using Web of Science and PubMed to include all original research 168 
articles written in English, published between January 1990 and March 2015, on the 169 
relationship between inter-individual variation and quercetin ADME in humans. The 170 
search strategies were as follows: “(quercetin OR kaempferol) AND human AND 171 
(bioavailability OR absorption) AND (in vivo OR clinical OR intervention OR 172 
volunteer) NOT review” and 298 abstracts were retrieved. Updated searches were 173 
performed on March 2016 and July 2017 and retrieved 20 and 25 additional abstracts, 174 





respectively. Kaempferol was originally included as it is also a flavonol, but since no 175 
relevant papers on inter-individual variation in absorption were ultimately found, it 176 
was not considered further in this review. In phase 1, all studies identified by the 177 
search strategy were randomly split within reviewers. Based on the title and abstract, 178 
only studies that were associated with ADME parameters from human intervention 179 
studies with quercetin or quercetin food sources were kept for phase 2 of the data 180 
collection process. In vitro, animal studies, and human intervention studies that 181 
evaluated the impact of quercetin on the pharmacokinetics of other compounds, were 182 
excluded. In phase 2, the remaining studies, based on their abstracts, were again 183 
randomly split and distributed to authors and data from the papers were summarized in 184 
a tabulated form.  In order to standardize reporting of differences between individuals 185 
in the various studies, the data presented was further processed and made more 186 
consistent where necessary and possible. The literature search of human intervention 187 
studies in phase 1 on quercetin and quercetin-rich foods resulted in a total of 343 188 
potential publications for inclusion. A review of titles and abstracts reduced the 189 
number of relevant publications to 97, and, after screening the full publications 190 
according to predefined criteria, 55 articles met the inclusion criteria and were 191 
included in this review (Fig. 3).  192 
 193 
Design of Human Intervention Studies Examining Quercetin Bioavailability 194 
Papers on the absorption by volunteers of quercetin from raw foods, processed foods, 195 
and food extracts, or from quercetin in solution, powder, tablet or capsule, were 196 
included. Studies were divided by source of quercetin as follows: food (29 studies, 197 
Table 1), pure quercetin or its glycosides (17 studies, Table 2), mixed matrix of food 198 
with pure compounds (6 studies, Table 3) or food extracts (3 studies (data not shown)) 199 





(Wojcicki and others 1995, Schulz and others 2005, Correa and others 2014). In 200 
general, bioavailability was estimated by measuring quercetin derivatives or 201 
catabolites in blood or urine. Since quercetin is mostly found in several conjugated 202 
forms in vivo (Fig. 1), then the analytical procedure followed by most authors is to 203 
either attempt to measure as many of the conjugated forms as possible, or to hydrolyze 204 
the samples to give quercetin and/or methylated quercetin in the aglycone form, and 205 
then measure just the resulting aglycone forms. Thirty-five studies estimated quercetin 206 
absorption by measuring quercetin aglycone after hydrolysis, 12 studies estimated 207 
quercetin conjugates, and 5 studies reported measuring both conjugates and aglycone 208 
after hydrolysis in urine and/or plasma. The number of subjects, however, was usually 209 
relatively small (<10).  210 
 211 
Inter-Individual Variations in Quercetin Bioavailability in Studies without 212 
Explicit Individual Data 213 
Most studies on quercetin bioavailability present the data as concentrations in plasma 214 
or urine. The data over time are then used to estimate pharmacokinetic parameters 215 
such as cmax (the maximum concentration reached), Tmax (the time at which cmax is 216 
apparent), and the area under the curve (AUC) for each individual chemical species, 217 
and often the data are shown as concentration versus time curves. Most studies present 218 
the mean value of all of the volunteers together with a value for standard deviation, 219 
standard error of the mean or percentage coefficient of variation (% CV), and do not 220 
explicitly present data on individuals. Where not presented, the % CV was calculated 221 
using the standard deviation (SD) or standard error of the mean (SEM) by the formula 222 
CV=100×SD/mean, and SEM was converted to SD by the formula SD = SEM×√n, 223 
where n is number of volunteers. To provide an illustration of how the % CV and the 224 





inter-individual variation are related, theoretical data are used to demonstrate the 225 
relationship between typical inter-individual variation and a calculated % CV in Fig. 4. 226 
This should allow the reader to grasp what a % CV means in terms of person to person 227 
variation in any measured parameter. Real published data from studies on quercetin 228 
given to volunteers are shown in full in Tables 4-6. For analysis of inter-individual 229 
variation in plasma, we have only included studies where cmax and AUC values were 230 
presented, or could be calculated based on the data provided in the original paper. 231 
Because of the heterogeneity in quercetin sources in the studies with quercetin-232 
containing foods (see Table 1), only variability in studies with onion derived products 233 
were chosen to allow a more appropriate comparison.  234 
 235 
For most of the studies with onions, where the quercetin glucosides present are 236 
absorbed in the small intestine, and for pure quercetin glucosides, the CV for cmax for 237 
onions ranged from 38 to 48% (Table 4), and for quercetin glucosides from 34 to 45% 238 
(Table 6). For glycosides other than glucosides, the CV values appear higher: cmax CV 239 
was 58-80% (Table 6). This suggests that the % CV could be lower when the site of 240 
absorption is the small intestine compared to when it occurs in the colon (including the 241 
action of the microbiota). Although these data are far from conclusive, we can 242 
hypothesize that compounds which undergo microbial metabolism in the colon exhibit 243 
a greater inter-individual variation than compounds absorbed in the small intestine. 244 
This hypothesis could be tested systematically for quercetin in the future and in 245 
addition could apply to other compounds. The work of Graefe and co-workers (Graefe 246 
and others 2001) follows the same trend and is consistent with this hypothesis, but all 247 
of the values for cmax are higher than those from the other papers (see Table 4 and 6). 248 
When given as aglycone, quercetin absorption is highly dependent on solubility within 249 





the gastrointestinal tract. The proportion of quercetin which is solubilized will be 250 
absorbed in the small intestine, but the fraction of quercetin which is out of solution 251 
will not be absorbed and will pass to the colon; part will be absorbed at that site after 252 
microbe-catalyzed deglycosylation, but part will be catabolized by gut microbiota into 253 
lower molecular mass compounds. With administration of quercetin as a pure 254 
compound, the inter-individual variation (CV) in cmax ranged from 29 to 54%, which is 255 
similar to the above values for absorption from the small intestine for food. These data 256 
therefore imply that the extent of inter-individual variation is not dependent on food or 257 
supplement source, provided that the chemical form is the same in each tested food or 258 
supplement. 259 
 260 
Pathways of Quercetin Conjugation and Metabolism 261 
Many conjugates and catabolites from quercetin in humans have been identified. Most 262 
of the studies considered here focused on the concentration of quercetin and 263 
potentially also of isorhamnetin and tamarixetin in samples (plasma, urine) treated by 264 
de-conjugating enzymes (usually crude β-glucuronidase/sulfatase from Helix pomatia) 265 
or submitted to acidic hydrolysis (Spencer and others 1999, Cermak and others 2003, 266 
Day and others 2003, Paulke and others 2012), which does not allow for the precise 267 
identification of the conjugated metabolites. In older publications, determination of 268 
quercetin using HPLC with UV-Vis (Spencer and others 1999, Day and others 2003) 269 
or fluorescence (Ader and others 2000) was used with relatively low sensitivity. 270 
Quercetin conjugates are now most frequently measured using HPLC/MSn techniques 271 
(Mullen and others 2004, Stalmach and others 2009, Borges and Crozier 2012, 272 
Valentová and others 2014), where quercetin, quercetin-3-O-glucuronide, quercetin 273 
glucuronide sulfate (without determination of the conjugation positions), 274 





isorhamnetin-3-O-glucuronide, quercetin-3´-O-sulfate and isorhamnetin have been 275 
identified in human plasma (Day and others 2001, Mullen and others 2006, Murota 276 
and others 2010). Identification of the exact position of conjugation is, in most cases, 277 
impossible without authentic standards with known exact structure, confirmed by 278 
nuclear magnetic resonance. 279 
 280 
During catabolism in the colon by the microbiota, C-ring fission is the predominant 281 
reaction in quercetin degradation. Subsequent products can then be absorbed by the 282 
colon epithelial cells, conjugated by mammalian phase II enzymes, and then ultimately 283 
be excreted in the urine, or alternatively a proportion may not be absorbed and appear 284 
directly in the feces. Significant increases in urinary concentrations of 4-ethylphenol, 285 
benzoic acid, and 4-ethylbenzoic acid were noted in healthy men after oral 286 
consumption of 200 mg of pure quercetin (Loke and others 2009). After 287 
supplementation with quercetin-3-O-rutinoside, phenylacetic acids, namely 3-288 
hydroxyphenylacetic acid (36% of the dose ingested), 3-methoxy-4-289 
hydroxyphenylacetic acid (8%) and 3,4-dihydroxyphenylacetic acid (5%) were 290 
excreted into the urine of healthy humans. The absence of a conventional microbiota, 291 
as in ileostomist subjects, abolished the formation of the majority of the phenolic acid 292 
metabolites, indicating the importance of bacterial biotransformation in formation of 293 
these compounds (Olthof and others 2003).  294 
 295 
Table 7 summarizes qualitatively all of the studies where the presence of a metabolite 296 
is reported, or has been definitely identified as absent. The most commonly identified 297 
conjugates where a single moiety has been added are quercetin-3′-O-sulfate, quercetin-298 
3-O-glucuronide and quercetin-3′-O-glucuronide. Quercetin was also methylated and 299 





glucuronidated, forming isorhamnetin-3-O-glucuronide and isorhamnetin-4′-O-300 
glucuronide, but it appears that methylation prevents subsequent sulfation and vice 301 
versa. Quercetin can also be doubly substituted with both sulfate and glucuronide 302 
groups, and in some papers detection of methylated quercetin which has been 303 
diglucuronidated was reported. There is also some evidence for quercetin substituted 304 
with both a glucose and a sulfate or glucuronide, but it is not clear if a small amount of 305 
quercetin was absorbed in the form of a glucoside and then further conjugated, or if 306 
the glucosylation occurred post-absorption (Mullen and others 2004, Mullen and 307 
others 2006). Some microbial metabolites of quercetin were identified when rutin was 308 
given in pure form or in tomato juice, and these include phenylacetic and 309 
hydroxyhippuric acid derivatives (Olthof and others 2003, Jaganath and others 2006). 310 
Quantitative data on the presence of quercetin conjugates and microbial metabolites 311 
are given in Table 8. Some metabolites such as quercetin-3′-O-sulfate are found only 312 
in plasma and not in urine, whereas many conjugates are found in both urine and 313 
plasma.  314 
 315 
Assessment of Individual Papers Where Data on Inter-Individual Variation are 316 
Specifically Presented 317 
 318 
Specific information on the inter- or intra-individual differences in quercetin 319 
bioavailability was available from 10 studies. Of these, 6 show the data in graphical 320 
form only (Boyle and others 2000a, Boyle and others 2000b, Davalos and others 2006, 321 
Moon and others 2008, Loke and others 2009, Petersen and others 2016), 1 presents 322 
results based on radio-scintillation counting (Walle and others 2001) and only 3 323 
provide numerical quantitative data for individual volunteers (Ferry and others 1996, 324 





Moon and others 2000, Jaganath and others 2006). The form of presentation differs 325 
substantially for each of these publications, which are discussed below. 326 
 327 
Uptake of quercetin from food was evaluated in 6 healthy non-obese 328 
normocholesterolemic non-smoking female volunteers in a randomized 2 phase cross-329 
over single dose supplementation trial using a meal of fried onions (200 g, phase 1) or 330 
fried onions (200 g) with fresh cherry tomatoes (100 g, phase 2) (Boyle and others 331 
2000b) (Table 1). Wash-out periods of 7 d were controlled by a validated food 332 
questionnaire and weighed intake record, and plasma concentration of quercetin 333 
confirmed compliance. Predominant flavonoids present in plasma were identified as 334 
“quercetin-3-glucoside” and “isorhamnetin-3-O-glucoside” by HPLC with UV and 335 
fluorimetric detection, but are more probably glucuronides since the authors did not 336 
have the appropriate glucuronide standards at the time. Inter-individual variation in the 337 
extent of “quercetin-3-O-glucoside” (that is quercetin-3-O-glucuronide) absorption 338 
into plasma, and also the time at which the highest concentration was present in the 339 
plasma, was observed. Individual data for plasma concentration for 2 main flavonols 340 
in plasma are presented as bar graphs at time points -24, 0, 4, 8 and 24 h for the first 341 
phase only and difference between the highest and lowest responder at 4 h after 342 
ingestion can be estimated as approximately one order of magnitude (about 20 343 
compared with 300 nM). In the second phase, total plasma concentration of quercetin 344 
measured in hydrolyzed samples was presented as mean ± SEM with CV 24%. This 345 
study also evaluated oxidation stress related plasma markers but these were displayed 346 
as mean ± SEM only and thus cannot be related to plasma levels of quercetin. 347 
 348 





Individual plasma quercetin concentration-time profiles for 10 individuals after 7 d 349 
supplementation with 500 mg of quercetin in capsule form 3 times daily (measured for 350 
8 h over the last day of the supplementation period) were published separately together 351 
with numerical data as means, medians and range (Moon and others 2008) (Table 2). 352 
This study differs from all others in that no baseline level is presented in the paper and 353 
no dietary restriction or wash-out were applied for the (pre-) supplementation period, 354 
although ingestion of ‘quercetin products’ within 30 d was an exclusion criteria. The 355 
study focused on re-entry pharmacokinetics, and it is clear that some subjects showed 356 
re-entry peaks of quercetin conjugates and other did not. The absorption rate constant 357 
and bioavailability also showed high inter-individual variability. From the individual 358 
plasma profiles, 2 subjects can be assigned as low responders (plasma concentration ≤ 359 
3 nM throughout the measurement period), and at least 5 as high responders (peak 360 
concentration ≥ 25 nM). Peak concentrations of quercetin aglycone and conjugated 361 
metabolites varied from 1.6 to 132.1 and 533 to 4000 nM, respectively. No 362 
determinants for the variability observed are available. Individual plasma profiles of 363 
quercetin concentration were presented also for a pharmacokinetic study with rutin 364 
(Boyle and others 2000a)(Table 2). In this case, however, the profiles were measured 365 
in only 3 female volunteers following a single dose of 500 mg rutin. Subjects showed 366 
different kinetics, with 2 having maximal plasma level at 7 h and the third at 4 h. The 367 
extent of absorption varied between 130 and 730 nM and the rate of clearance was also 368 
highly variable. The authors then performed a 6 wk placebo controlled 369 
supplementation study (n = 8 in each group, 500 mg rutin/d). While the plasma level 370 
of quercetin, kaempferol and isorhamnetin before and after the study were presented as 371 
bar graphs using means and SEM, individual bar graphs are available for plasma “total 372 





phenols” (using the Folin-Ciocalteu assay) at weeks 1 and 5. In this case, there was no 373 
clear high or low responder, with the range between ~11 and 15 µg/mL).  374 
 375 
Data were presented individually for 12 healthy men using line graphs for plasma and 376 
urinary total quercetin before, and 2 or 5 h after supplementation with a single dose of 377 
200 mg of quercetin in a cross-over design including the control but also ( ̶ )-378 
epicatechin and ( ̶ )-epigallocatechin gallate (EGCG, 1 wk wash-out between 379 
treatments, (Loke and others 2009) (Table 2). There were apparently high and low 380 
responders (4 subjects with 4-5 fold increase and at least 2 subjects with a slight 381 
increase). More importantly, this study also evaluated 11 aromatic phenolic 382 
compounds that increased significantly in the urine of the participants, probably 383 
catabolites from flavonoid microbial degradation. Unfortunately, these data are not 384 
presented individually, and, therefore, we cannot conclude if low response in plasma 385 
or urine quercetin concentration is related to the (increased) level of microbial 386 
metabolites. However, significant increases occurred in urinary excretion of 4-387 
ethylphenol (increased in 100% of participants), benzoic acid (83%), and 4-388 
ethylbenzoic acid (83%), which all significantly correlated with the changes in plasma 389 
and urinary total quercetin. Moreover, 67% of the participants showed increased 390 
urinary excretion of 2-methoxyphenylacetic acid and 3-phenylpropionic acid, and 58% 391 
for 3-(4-hydroxyphenyl)-propionic acid (Loke and others 2009). A similar form of 392 
data presentation using line graphs was chosen also for a parallel single-treatment 393 
supplementation study with grape juice (n = 14) and fried onions (n = 2), but for 394 
quercetin plasma level at 0 and 2 h in placebo (n = 6) and grape juice treatment groups 395 
only (Davalos and others 2006) (Table 1). The limitation of this study is a high 396 
baseline level of quercetin (there was only 24 h “wash-out” before the intervention 397 





during which the volunteers were “advised” to refrain from quercetin containing food, 398 
with no compliance control) and also a very low number of subjects in the onion 399 
group. A decrease in plasma quercetin level from ~130 to 80 and 50 nM was observed 400 
in 2 volunteers from the placebo group. In the grape juice group, 7 subjects displayed 401 
no increase in plasma quercetin and there was only one relatively high responder (2-402 
fold increase). Mean plasma concentration was 46 nM with SD 20 nM (CV 43%). This 403 
might be related to very low quercetin intake (4.9 mg) from the grape juice or 404 
measurement too early after administration. 405 
 406 
Bioavailability of quercetin from 4 different sources (apple peel, vacuum impregnated 407 
apple chips, apple peel extract capsules, and quercetin dihydrate capsules, all 408 
providing 71 µmol of quercetin equivalents) was investigated in 6 healthy subjects 409 
(Petersen and others 2016) (Table 3). This single dose, diet-controlled, cross-over 410 
study had 1 wk wash-out periods before the study and between each treatment. The 411 
compliance seems to be satisfactory with no measurable quercetin and total flavonols 412 
at baseline (estimated from plasma concentration curves). Plasma pharmacokinetic 413 
parameters and quercetin plasma concentration curves were presented as mean ± SEM, 414 
but individual AUC0-24 h values were also shown in graphical form (bar graphs) 415 
separately for each treatment. Individual response varied substantially and allowed the 416 
authors to divide the participants into subgroups of high and low responders, with the 417 
difference in AUC being up to 10-fold higher in the highest responder compared with 418 
the lowest (estimated from the bar graphs, (Petersen and others 2016).  419 
 420 
Absorption and disposition of 14C-radiolabelled quercetin was studied in 6 healthy 421 
subjects after oral and intravenous (i.v.) administration (Walle and others 2001) (Table 422 





2). Data are presented individually, but also as mean ± SEM. The main limitation of 423 
this study is that quercetin was 14C-labeled only on the C-4 position of the C ring. 424 
Although this was a cross-over study, only 4 subjects followed both oral and 425 
intravenous treatment, and recovery in the exhaled air after both treatments is available 426 
for only 1 volunteer. On the other hand, radioactivity was measured not only in urine 427 
and plasma, but also in feces and expired air with individual volunteer data presented 428 
in a tabulated form. The CV calculated in this study was ~27 and 14% for AUC (37 – 429 
68 and 0.30 – 0.37 µmol.h/L for oral and intravenous dose, respectively) and 21 and 430 
18% for radioactivity recovery from urine (3.3 – 5.7% and 18.4 – 26.8% for oral and 431 
intravenous dose, respectively). A large variability was found for the recovery of 432 
radioactivity from exhaled air. In some individuals, 14CO2 started to appear 4 h after 433 
administration and in others not until 8 h, and therefore, 14CO2 in the expired air 434 
represented 23.0-81.1% of the radioactivity administered. Taking into account the 435 
limitations of this study, 2 volunteers can however probably be classified as relatively 436 
high responders (AUC 65.5, 68.0 and 0.37, 0.39 µmol.h/L for oral and intravenous 437 
dose, respectively; urine recovery 5.4, 5.7 and 20.1, 19.7%), but recovery as 14CO2 is 438 
known for intravenous dose only and differs markedly (81.1 and 25.5% of the 439 
radioactivity administered)(Walle and others 2001).  440 
 441 
Quercetin concentration in human plasma from 7 volunteers was determined before 442 
and after a short-term ingestion of onions (Moon and others 2000) (Table 1). The 443 
subjects were given diets containing onion slices (67.6-93.6 mg of quercetin 444 
equivalents /d) with meals for 1 wk.  After 10 h of fasting, quercetin was measured in 445 
plasma after β-glucuronidase-sulfatase treatment, and the concentration increased on 446 
average 16-fold after the 1-wk trial. However, individual data again indicated a 447 





substantial variation between volunteers, some with a very low response (8-fold, 448 
calculated from data) compared to others with a higher response (27-fold, calculated 449 
from data). In a Phase I clinical trial, quercetin was administered by short intravenous 450 
infusion at escalating doses at 3-wk intervals in cancer patients (Ferry and others 451 
1996) (Table 2). Quercetin pharmacokinetics were defined during the first 3 h at 452 
frequent intervals, and individual plasma profiles were plotted for 7 tested doses in 7 453 
different patients. By analyzing the curves, it is clear that the patients responded 454 
differently to quercetin administration. For example, 1 patient given a dose of 630 mg 455 
quercetin/m2 showed, after 120 min, a circulating blood level of quercetin lower than a 456 
patient on 200 mg/m2. This variation is also reflected in the parameters calculated by 457 
pharmacokinetic modelling for 14 patients (shown in Fig. 5). For 7 patients treated 458 
with 945 mg quercetin/m2, the mean amount of quercetin excreted in urine ranged 459 
from 0.03 to 7.6% of the dose administered, also indicating a considerable inter-patient 460 
variability. In this study quercetin levels were determined after intravenous injection, 461 
which eliminates variables derived from microbiota and intestinal absorption, 462 
suggesting that variation in quercetin metabolizing enzymes and transporters 463 
contribute highly to inter-individual variability.  464 
 465 
In order to study the contribution of the small and large intestine to the absorption and 466 
metabolism of rutin in humans, a study was conducted with a single dose of tomato 467 
juice containing rutin (176 µmol) by healthy volunteers and ileostomists (Jaganath and 468 
others 2006) Table1). Quercetin-3-O-glucuronide and isorhamnetin-3-O-glucuronide 469 
were absent at baseline, and were measured at 4, 5, 6, 7 and 8 h post-ingestion. The 470 
authors note a high extent of variation between the volunteers, and also for excretion 471 
of urinary metabolites. Over a 24 h period, 1 of the volunteers excreted a total of 4981 472 





nmol of metabolites corresponding to 2.8% of the ingested dose of rutin. In contrast, 473 
excretion by the other subjects ranged from 40 to 608 nmol, equivalent to 0.02–0.35% 474 
of intake. The lower level of excretion of rutin metabolites by volunteers was limited 475 
to isorhamnetin-3-O-glucuronide and the 3-, 3′- and 4′-glucuronides of quercetin. The 476 
authors conclude that this large inter-individual variation, either in plasma or urine, 477 
may be related to the dependency of rutin metabolism on the microbiota. The low 478 
urinary recovery of the ingested rutin as glucuronides, glucosides and methylated 479 
metabolites of quercetin, and identification of low molecular weight phenolic acids 480 
metabolized by microbiota, suggest that the latter may account for the most significant 481 
proportion of the metabolism of rutin/quercetin. No individual data were presented for 482 
the low molecular weight phenolic acids, but CV for total levels of excretion varies 483 
from 24% for 4-hydroxyhippuric acid to 77% for 3-methoxy-4-hydroxyphenylacetic 484 
acid (estimated). Importantly, this study highlights that an individual who would be 485 
considered a low responder as judged by evaluating glucuronides, glucosides and 486 
methylated metabolites of quercetin, may actually be revealed as a faster metabolizer 487 
and therefore higher responder when assessed by the concentration of low molecular 488 
weight phenolic acids. This highlights that a precise understanding of inter-individual 489 
variability of quercetin bioavailability requires measurement of all metabolic routes, 490 
including the gut microbiota.  491 
 492 
Factors Affecting Inter-Individual Variation in Quercetin Bioavailability 493 
The present paper clearly indicates that a substantial inter-individual variability in 494 
quercetin bioavailability is observed in all studies. Given the complexity of the 495 
pathways of metabolism which is obvious from Fig. 1 and 2, inter-individual variation 496 
in quercetin metabolism can arise from numerous factors. These can include, but are 497 





not limited to, genetic polymorphisms, dietary adaptation, composition of gut 498 
microbiota, drug exposure, and other subject characteristics such as BMI and health 499 
status. There are several genetic polymorphisms in the enzymes and transporters 500 
shown in Fig. 1, which could account for some variability. Polymorphisms have been 501 
reported for LPH (Flatz and Rotthauwe 1977), UGTs (Sugatani 2013), COMT (Ding 502 
and others 2010), SULTs (Glatt and others 2000, Rossi and others 2004), ABC 503 
transporters (Kerb and others 2001) and OAT transporters (Fujita and others 2005). 504 
However, to date, none of the studies have examined the contribution that these 505 
polymorphisms might make to quercetin metabolism in vivo. In addition, many of 506 
these enzymes and transpo ters are modulated by diet, drugs and environment, adding 507 
an additional layer of complexity.  508 
 509 
Conclusions and Future Recommendations 510 
 511 
An important and probably the most essential question which has not yet been 512 
addressed is the presence of any link between bioavailability and bioefficacy. Such a 513 
study would address the hypothesis: Does a high absorber of quercetin also show a 514 
greater biological response to quercetin? This is complicated by the gut microbiota, 515 
and one could equally ask the question: Does the presence of high quantities of 516 
microbial metabolites correlate with a more pronounced biological response? 517 
Recently, the role of inter-individual variability on the impact of flavonols on 518 
cardiometabolic biomarkers was investigated but owing to lack of data, effects could 519 
not be correlated with bioavailability (Menezes and others 2017).  520 
 521 





Further studies designed specifically to address inter-individual variation are needed. 522 
At least moderately larger (n ≥ 20) studies presenting individual data for 523 
pharmacokinetics of quercetin (and glycosides occurring in foods) including parent 524 
compound and most known low molecular weight metabolites, together with the 525 
details about the study subjects such as their age, gender, genotype, composition of gut 526 
microbiota, diet, life style and health status are necessary to address this knowledge 527 
gap in the future. Ideally this information would be coupled with bioactivity and 528 
biomarker measurements. The most important aspect for future studies to consider, but 529 
in some ways the most difficult to address, is to determine if a “low responder” 530 
exhibits a smaller response in a health biomarker compared to a “high responder”.  531 
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Table 1 Characterization of intervention studies using food as quercetin source 975 
Food matrix 
(raw/ processed) 













Lightly fried onions and 
fresh cherry tomato 
4 wk 
Single dose, cross-over: 
1 wk wash-out → Phase 1 → 
2 wk wash-out → Phase 2 
Phase 1: 200 g onions 
Phase 2: 200 g onions + 
100 g tomatoes 
6 (F) Plasma 
Hydrolysis 
and native 
(Boyle and others 
2000b) 
Red grape juice and 
fried onions 
1 d 
Single dose, parallel placebo 
controlled 
100 mL grape juice or 200 g 
onions 
22 Plasma Hydrolysis 
(Davalos and others 
2006) 
Black tea and fried 
onions 
3 wk 
Repeated, cross-over in 
random order: 
4 d wash-out → 3 d 
intervention, 2 times 
1600 mL tea or 129 g 
onions in 2-3 portions/d 




(de Vries and others 
1998) 
Red wine, fried yellow 
onions and black tea 
3 wk 
Repeated, cross-over in 
random order: 
3 d wash-out → 4 d 
intervention, 3 times 
750 mL wine or 50 g onions 
or 375 mL tea 






(de Vries and others 
2001) 
Onion paste 1 d Single dose 
350–500 g of paste (2.3 mg 
of quercetin /kg body 
weight) 
4 Plasma Native 
(Kawai and others 
2008) 
Fried red onions 1 d Single dose 270 g onions (275 ± 8.8 6 (2 F) Plasma Native (Mullen and others 





µmol of total flavonols) and urine 2004, Mullen and 
others 2006) 
Sautéed yellow onions 
with ketchup and Italian 
seasonings 
1 d Single dose 
76 – 150 g of onion meal 
(10.9 to 51.6 mg of 
quercetin glycosides) 
4 (3 F) 
ileostomists 
Plasma Native 
(Walle and others 
2000) 
Cooked onion slices 1 wk Repeated daily 
260 – 360 g (67.6–93.6 mg 
quercetin equivalents)  in 3 
portions/d 
7 (F) Plasma Hydrolysis 
(Moon and others 
2000) 
Shallot flesh or dry skin 1 d 
Cross-over, single doses 
separated by 7 d wash-out 
1.4 mg quercetin/kg body 
weight 







Random parallel, controlled, 
repeated once a day 
100 g berries (12.3 ± 1.4 
mg quercetin)/d in addition 
to normal diet 
40 (M) Plasma Hydrolysis 
(Erlund and others 
2003) 
Black currant juice 1 wk Partial crossover, single dose 
4.4 or 2.7 g juice/kg body 
weight or  2.7 g juice/kg 
body weight + rice cake 
17 (F) 
Plasma Hydrolysis 






Random parallel, repeated 
once a day 
100 g berries (12.3 ± 1.4 
mg quercetin)/d in addition 
to normal diet 
60 (M) 
Berries, other fruits and 
vegetables 
6 wk 
Random parallel, dietary 
controlled 
24.1 mg quercetin/d 80 (F+M) 





Vegetable diet 15 wk 
Cross-over, dietary controlled: 
2 wk wash-out → 5 wk 
intervention → 3 wk wash-out 
→ 5 wk intervention 
Low-vegetable diet: 60 mg 
of vitamin C, 8 mg of 
vitamin E and 200 mg of 
folate/d.  
High-vegetable diet: 480 mg 
of vitamin C, 16 mg of 
vitamin E, 10 mg of β-
carotene and 600 mg of 
folate/d 
37 (F) Plasma Native 
(Erlund and others 
2002) 
Conventionally (CPD) 




randomized, dietary controlled: 
1 wk run-in → 3 wk 
intervention → 3 wk wash-out 
→ 3 wk intervention 
CPD: 2632 ± 774 µg 
quercetin /d; OPD: 4198 ± 





and others 2003) 
Cloudy apple juice 1 d Single dose 1 L of juice 
5 (3 F) Plasma 
Hydrolysis 
(Kahle and others 
2011) 6 (4 F) Urine 
Whole bilberries, nectar 
of lingonberries, black 
currant-strawberry 




controlled parallel dietary 
intervention, repeated daily 
160 g of berries (4.9 mg 







(Koli and others 
2010) 






Juice mix 1 d Single dose 
6.3 mL of juice  






(Krogholm and others 
2010) 
Grape juice preparation 8 wk 
Sequential single doses with 2 
wk wash-outs 
200, 400, 600, 1200 mL 





(Meng and others 
2004) 
Blueberry juice mixture 
with apple juice 
4 wk 
Controlled dietary intervention, 
repeated daily 
. 
1L of juice mixture (18 mg 
quercetin)/d 
8 (F) Plasma Hydrolysis 
(Wilms and others 
2005) 
Fruit juice (black currant 
and apple juice) 
3 wk 
Cross-over, repeated 
1 wk interventions separated 
by 2 wk 
750, 1000, and 1500 mL 
(4.8, 6.4, and 9.6 mg 
quercetin/d) 




(Young and others 
1999) 
Tomato puree 2 wk Repeated once/d 
25 g purée (2.3 mg 
quercetin glycosides) plus 5 
g of olive oil 
12 F Plasma Native 
(Mauri and others 
1999) 




(Jaganath and others 
2006) 
Decaffeinated coffee 
powder, green tea 
extract, cocoa powder, 
grape skin extract, grape 
14 d 
Cross-over, single doses in a 
randomized order at intervals 
of 14 d 
4 g coffee/200 mL,  
0.3 g tea extract/200 mL 
10 g cocoa powder/200 mL 
18 g grape-skin 
9 (5 F) Urine Hydrolysis (Ito and others 2005) 





and orange juices extract/200 mL 
430 mL grape fruit extract 
and 
550 mL orange juice 
Green tea 1 d Single dose 340 mL of commercial tea 2 (M) Plasma Hydrolysis (Jin and others 2004) 
Apple peel and onion 3 d 
Randomized crossover, 2 d 
wash-out and single dose 
85 g of apple peel or 47.5 g 
of onion  with 100 g of 
applesauce 
16 (8 F) Plasma Native 
(Lee and others 
2012) 
Onion and Tofu 1 d Crossover, single dose 
170-250 g of sautéed onion 
or 170-250 of tofu with soy 
sauce or combination of the 
2 dishes 
5 Plasma Hydrolysis 
(Nakamura and 
others 2014) 
Fried onion 1 d Single dose 200 g 4 (2 F) Plasma Native 
(Day and others 
2001) 
Onion 1 d 
Randomized crossover, single 
dose 
Control: 25 g of glucose in 
400 mL of water 
368 g of cooked white 
onions or cooked yellow 
onions 




and others 2004) 
Cranberry juice 3 d 
Randomized crossover single 
dose, 2 d wash-out 
240 mL 10 (F) Urine Native 
(Wang and others 
2016) 







  978 





Table 2 Characterization of studies using quercetin and derivatives as pure compounds 979 
Class 
Study design 




















over, double blind, diet controlled, 
single doses in ascending dosages; 
wash-out 2 – 3 d between doses and 9 
d between interventions 




Plasma Hydrolysis (Erlund and others 2000) 
3 wk 
Randomized, cross-over, single dose, 
wash-out 1 wk 
1095 mg quercetin 
with low, moderate 





Hydrolysis (Guo and others 2013) 
12 wk 







Plasma Hydrolysis (Jin and others 2010) 
1 d 
Cross-over, placebo-controlled, single 
dose 
200 mg quercetin 12 (M) 
Plasma and 
urine 
Hydrolysis (Loke and others 2009) 
3.5 wk 
Randomized double-blind parallel, 
placebo controlled repeated daily 
1000 mg quercetin in 
2 portions/d 
20 (M) Plasma Hydrolysis 
(McAnulty and others 
2008) 
1 d Single doses, parallel 0.5 or 1 mg/kg 2 (M) Plasma and Hydrolysis (Meng and others 2004) 






1 wk Open, repeated 
1500 mg quercetin in 
3 portions/d 
10 (4 F) 
Plasma and 
urine 
Hydrolysis (Moon and others 2008) 
1 d Open, single dose 
2 mg of quercetin 
eq./kg body weight 
5 (1 F) Plasma Hydrolysis (Murota and others 2010) 
2 wk Partial cross-over, single dose 
100 mg quercetin 
(per os);  
2.5 mg quercetin 
(intravenous)a 





Native (Walle and others 2001) 
1 d Parallel, single dose 
50 – 2000 mg/m3 
(intravenous) 
51 (25 F) 
Plasma and 
urine 










Cross-over, single doses in random 




9 Plasma Hydrolysis (Hollman and others 1999) 
4 wk 
Randomized 2-interventions cross-
over, double blind, diet controlled, 
single doses in ascending dosages; 
wash-out 2 – 3d between doses and 9 
d between doses and periods 
interventions 
16, 40, 100 mg rutin 12 (5 F) Plasma Hydrolysis (Erlund and others 2000) 
3 mo Cross-over, controlled, various  single 0/150/300 mg 6 (3 F) Plasma Hydrolysis (Hubbard and others 





doses, 1 mo wash-out quercetin-4′-O-
glucoside 
2004) 
1 d Open, single dose 500 mg rutin 3 (F) 
Plasma Hydrolysis (Boyle and others 2000a) 
6 wk 
Parallel, placebo controlled, repeated 
daily 
500 mg rutin / d 8 (F) 
1 d Open, single dose 
2 mg of quercetin 
glycosides eq./kg 
body weight 
5 (1 F) Plasma Hydrolysis (Murota and others 2010) 
4 wk 
Dietary and placebo controlled cross-
over, 1 wk each treatment, no wash-out 
440 mg rutin 20 (10 F) Urine 
Hydrolysis 
and native 
(Olthof and others 2003) 
16 d 
Single doses in 2 different days (d 7 
and d 13) in random order 





9 (4 F) Plasma 
Hydrolysis 
and native 
(Sesink and others 2001) 
a Quercetin source was radiolabeled and sample analysis was based on scintillation counting 980 
 981 





Table 3 Characterization of studies with mixtures or combinations of fruits/vegetables with pure compounds 982 













Onion skin extract enriched 
cereal bars / capsules with 
pure quercetin 
3 wk Cross-over, single-blind, 
single dose, 1 wk run-in, 2 
wk wash-out 
130 mg quercetin 
equivalents 
6 (F) Plasma Hydrolysis (Egert and others 2012) 
Quercetin supplemented in 
white wine / grape juice / 
vegetable juice 
8 wk Cross-over, open, random 




4 (M) Plasma and 
urine 
Hydrolysis (Goldberg and others 
2003) 
Stewed onions/ quercetin-4′-O-
glucoside / buckwheat tea 
powder/ quercetin-3-O-
rutinoside 
10 d Randomized cross-over, 3 
d run-in, single doses with 
24 h wash-out 
100 mg or 200 mg 
quercetin 
equivalents 




(Graefe and others 2001) 
Onion supplement / rutin / 
quercetin tablets 
3 d Randomized cross-over, 
12 d run-in, single doses 




9 (5 F) Urine Hydrolysis (Hollman and others 1995) 
Fried onions / apples / pure 
rutin 
12 d Cross-over, single doses, 
12 d run-in, with 3 d wash-
64/100/100 mg 
quercetin 
9 Plasma Hydrolysis (Hollman and others 
1997b) 






Quercetin dihydrate capsules / 
apple chips, apple peal extract 
capsules, apple peel 
4 wk Randomized, diet 
controlled, cross-over, 
single doses, 1 wk wash-
out 
71 µmol quercetin 
equivalents 
6 (F) Plasma Hydrolysis (Petersen and others 
2016) 
 983 





Table 4 Coefficient of variation in pharmacokinetic parameters when raw and cooked onions 984 
were administered and quercetin was measured after hydrolysis (derived from the studies 985 
shown in Table 1).  986 
 987 













63 (Graefe and others 2001) 
48, 39b (de Pascual-Teresa and others 2004) 
38, 47c (Wiczkowski and others 2008) 
AUC(0-24) 71 (Graefe and others 2001) 




42 (de Vries and others 1998) 
43 (de Vries and others 2001) 
47 (Hollman and others 1995) 
 988 
a % CV was calculated for the parameters with available mean and SD or SEM data by the 989 
formula CV=100×SD/mean. b yellow and white onions, respectively, c flesh and dry skin, 990 
respectively. 991 
  992 





Table 5 Variations in bioavailability studies on quercetin (details for each study in Tables 2 993 
and 3) administered as pure compound.  994 











29b (Erlund and others 2000) 
35, 31, 
54c 
(Guo and others 2013) 
25, 37d (Egert and others 2012) 
54 (Petersen and others 2016) 
AUC 27, 14e (Walle and others 2001) 
AUC(0-24) 25b (Erlund and others 2000) 




(Guo and others 2013) 
AUC 37, 25d (Egert and others 2012) 
AUC0-24 47 (Petersen and others 2016) 
Urine 
 
21, 18e (Walle and others 2001) 
Feces 77, 44e (Walle and others 2001) 
CO2 21, 88e (Walle and others 2001) 
a % CV was calculated for the parameters with available mean and SD or SEM data  b 995 
Calculated for 3 different doses at upper and lower confidence interval (CI) using the formula 996 
SD = |Mean-CI|/z×√n with z=1.96 and 1.65 for 95% and 90% CI, respectively, and expressed 997 
as mean, n = 6 (3 doses, 2 lower and upper interval), c low, moderate and high fat meal 998 
respectively, d quercetin enriched cereal bars and quercetin capsules respectively, e 100 mg 999 
per os and 0.3 mg intravenous, respectively, of radiolabelled quercetin and sample analysis 1000 
by scintillation counting.  1001 





Table 6 Variation in pharmacokinetic parameters when quercetin glycosides were 1002 
administered (derived from the studies shown in Tables 2 and 3). 1003 

















80b (Erlund and others 2000) 
58 (Hollman and others 1999) 
108 (Graefe and others 2001) 
AUC(0-32) 47b (Erlund and others 2000) 
AUC(0-∞) 50 (Hollman and others 1999) 
AUC(0-24) 88 (Graefe and others 2001) 
AUC(0-24) 54b (Erlund and others 2000) 
Urine 
Amountc 24 (Olthof and others 2003) 



















45d (Hollman and others 1999) 
40, 34d (Hubbard and others 2004) 
41e (Murota and others 2010) 
77d (Graefe and others 2001) 
AUC(0-24) 108d (Graefe and others 2001) 
AUC 32e (Murota and others 2010) 
AUC(0-∞) 34d (Hollman and others 1999) 
 
1004 
a Calculated for the parameters with available mean and SD or SEM data. b Calculated for 3 1005 
different doses at upper and lower CI using the formula SD = |Mean-CI|/z×√n with z = 1.96 1006 
and 1.65 for 95% and 90% CI, respectively, and expressed as mean, n = 6 (3 doses, 2 lower 1007 
and upper interval), c 16, 40 and 100 mg, respectively, d quercetin-4ʹ-O-glucoside, e 1008 
enzymatically modified quercetin-3-O-glucoside.  1009 





Table 7 List of main quercetin metabolites identified in non-hydrolyzed samples (presence 1010 
indicated by +, Nd-not detected) 1011 
















(Mullen and others 2006) 
(Kawai and others 2008) 
(Mullen and others 2004) 
(Nakamura and others 2014) 
(de Vries and others 1998) 
(de Pascual-Teresa and others 2004) 
(Lee and others 2012) 















(Mullen and others 2006) 
(Kawai and others 2008) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
(Lee and others 2012) 
(de Vries and others 1998) 





(Jaganath and others 2006) 

















(Kawai and others 2008) 
(Mullen and others 2006) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
(Lee and others 2012) 
(Nakamura and others 2014) 
(de Vries and others 1998) 
(de Pascual-Teresa and others 2004) 
Quercetin-7-O-glucuronide + + (Mullen and others 2004) 




(Mullen and others 2006) 
(Mullen and others 2004) 


















(Mullen and others 2006) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
(Lee and others 2012) 
(de Vries and others 1998) 











(Mullen and others 2006) 
(Kawai and others 2008) 
(Mullen and others 2004) 
(de Vries and others 1998) 
(de Pascual-Teresa and others 2004) 












(Mullen and others 2006) 
(Kawai and others 2008) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
(Lee and others 2012) 
(de Vries and others 1998) 








(Mullen and others 2006) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
(Lee and others 2012) 






(Kawai and others 2008) 
(Mullen and others 2004) 
(Lee and others 2012) 




(Mullen and others 2006) 









(Mullen and others 2006) 
(Mullen and others 2004) 
(Jaganath and others 2006) 
Quercetin glutathione +  (Lee and others 2012) 




(Olthof and others 2003) 
(Jaganath and others 2006) 









(Olthof and others 2003) 







(Olthof and others 2003) 
(Jaganath and others 2006) 
2-hydroxyhippuric acid Nd + (Jaganath and others 2006) 
3-hydroxyhippuric acid Nd + (Jaganath and others 2006) 
4-hydroxyhippuric acid Nd + (Jaganath and others 2006) 
 1012 
a In ref (Lee and others 2012), quercetin-3-O-sulfate was reported, but this is likely to be a 1013 
typographical error since the authors themselves give the structure of quercetin-3′-O-sulfate. 1014 





Table 8-Variability in kinetic parameters for quercetin metabolites based on studies with non-hydrolyzed samples with quantitative data 1015 
presented as mean values.  1016 
Conjugate Sample Kinetic data References 





Cmax 12.1 ± 16.5 
97.8 ± 81.8 
137d 
84e 
(Lee and others 2012) 
AUC0-24h 31.5 ± 45.4 
299 ± 227 
144d 
76e 
Quercetin-3′-O-glucuronide Urine Amount 1845 ± 193 26 (Mullen and others 2006) 
Quercetin-3-O-glucuronide Plasma Cmax 12 ± 2 17 (Jaganath and others 2006) 
Urine Amount 912 ± 149 40 (Mullen and others 2006) 
Quercetin glucuronide Plasma Cmax 31.5 ± 27.1 
433 ± 244 
86d 
56e 
(Lee and others 2012) 
AUC 75.9  ± 75.1 
1827 ± 1336 
99d 
73e 
Quercetin-glucuronide sulfate Plasma Cmax 2.3 ±8.4 
75.4 ± 113.4 
369d 
150e 
(Lee and others 2012) 
AUC 20.3 ± 76.4 
795 ± 1172 
375d 
147e 
Urine Amount 1229, 1384f 29, 38f (Mullen and others 2006) 





Isorhamnetin-3-O-glucuronide Plasma Cmax 4.3 ± 1.5 35 (Jaganath and others 2006) 
Urine Amount 1789 ± 239 33 (Mullen and others 2006) 
Isorhamnetin-4′-O-glucuronide Urine Amount 700 ± 114 40 (Mullen and others 2006) 
Quercetin diglucuronide Plasma Cmax 13.7 ± 22.3 
248 ± 137 
163d 
55e 
(Lee and others 2012) 
AUC 35.9 ± 59.7 
869 ± 431 
166d 
50e 
Urine Amount 2223 ± 417 46 (Mullen and others 2006) 
Methyl quercetin 
diglucuronide 
Plasma Cmax 5.2 ± 7.9 
94.2 ± 36.9 
150d 
39e 
(Lee and others 2012) 
AUC 61.3 ± 123.5 
1033 ± 409 
201d 
40e 
Urine Amount 426, 1003f 38, 57f (Mullen and others 2006) 
Methyl quercetin glucuronide Plasma Cmax 14.8 ± 17.2 
178 ± 61 
116d 
34e 
(Lee and others 2012) 
AUC 53.8 ± 82.7 
1008 ± 404 
153d 
40e 
Quercetin glucoside sulfate Urine Amount 392, 821f 37, 47f (Mullen and others 2006) 
Quercetin glucoside 
glucuronide 
Urine Amount 163 ± 23 35 (Mullen and others 2006) 
3-hydroxyphenylacetic acid Urine Amount 259 ± 51 88 (Olthof and others 2003) 







Urine Amount 52 ± 6 52 (Olthof and others 2003) 
3-methoxy-4-
hydroxyphenylacetic acid 
Urine Amount 103 ± 15 65 (Olthof and others 2003) 





a all values for Cmax, AUC and amount in urine are shown as nM, nM.h and nmol, 1017 
respectively; values were converted from the original papers if necessary. b %CV was 1018 
calculated for the parameters with available mean and SD or SEM data. c in (Lee and others 1019 
2012), quercetin-3-O-sulfate was reported, but this is likely to be a typographical error since 1020 
the authors themselves give the structure of quercetin-3′-O-sulfate, d apple peel powder, e 1021 
onion powder, f the same metabolite was identified and quantified at 2 retention times, values 1022 
presented correspond to the data for the 2 peaks.  1023 
  1024 








Fig. 1 Metabolism of quercetin to form conjugates.  1028 
Where information on the involvement of a specific enzyme is published (Boersma 1029 
and others 2002), then only the most active isoforms are indicated in the figure. When 1030 
the specific form is unknown, then the general notation of UGT (UDP-1031 
glucuronosyltransferase) or SULT (sulfotransferase) is used. For COMT (catechol-O-1032 
methyl transferase), LPH (lactase phloridzin hydrolase) and CBG (cytosolic β-1033 
glucosidase), only one form of the enzyme exists in humans. Information for this 1034 

























































































































and others 2001, Govind and others 2001, Hong and Mitchell 2004, Del Rio and 1036 
others 2013). 1037 
 1038 
  1039 








Fig. 2 Schematic representation of quercetin metabolism by gut microbiota 1043 
Information is taken from (Schneider and others 1999, Walle 2004, Harwood and 1044 
others 2007, Ramesova and others 2012, Serra and others 2012, Vacek and others 1045 
2012, Lu and others 2013, Valentová and others 2014); the speculative proposed 1046 
intermediate where the C-ring is opened is shown in grey. R1, R2, and R3 represent 1047 
substitution positions of sugars. The microbial conjugates from polyphenols are 1048 
mostly found conjugated with sulfate, or sometimes glucuronide groups (Clifford and 1049 
others 2013, Pimpao and others 2015). 1050 











Fig. 3  Scheme showing the literature search and revision process.  1054 
 1055 
  1056 
343 Records identified 
through database search 
(WOS, PUBMED) 
97 retained  after 
review of title and 
abstract
55 full-text retained as 
specifically associated 
with quercetin ADME 
Phase 1- exclusion of in vitro, 
animal studies and human studies 
that evaluated the impact of 
quercetin on the pharmacokinetics 
of other compounds.
Phase 2- Revision of full texts for 
predefined criteria







Fig. 4 Illustration of the variation in data expected from the reported CV value. 1059 
Theoretical maximum plasma concentration cmax data (cmax = 100) were calculated for 1060 
10 volunteers to allow a CV of 10, 50 and 90% to be calculated using the “STDEV” 1061 
function of the spreadsheet in the Microsoft Excel program. The x-axis shows the 1062 
“volunteer number” and the mean value (av) was set to 100%. Error bar shows the 1063 
standard deviation in the average values of volunteers 1-10. With a CV of 90%, the 1064 
data appears to stratify between “responders” and “non-responders”. 1065 
 1066 
  1067 







Fig. 5. Dependence of area under the curve (AUC) values on quercetin dose 1070 
(Ferry and others 1996). AUC values obtained by pharmacokinetic modelling for all 1071 
14 patients (each patient represented by a filled circle) for the tested doses of quercetin 1072 
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